Catamaran Bio is developing off-the-shelf chimeric antigen receptor (CAR) natural killer (NK) cell therapies to address a broad range of cancers. NK cells are critical components of the immune system that possess natural cancer-fighting properties. Catamaran is using synthetic biology and non-viral cell engineering to create novel CAR-NK cells that are capable of treating solid tumors by combining new functional attributes with their inherent cancer-killing properties. To achieve this, Catamaran developed TAILWIND®, their proprietary suite of technologies that CAR-NK cell therapy development and manufacturing for multiple cancer types. Catamaran’s lead candidate, CAT-248, has been engineered with four functional modifications and will be tested in clinical studies for renal cell carcinoma.

<p>Claim company profile to add description</p>


Catamaran Bio

Founded: 2020
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Breast cancer, gastric cancer
Drug types: ONC
Lead product: CAT-179
Funding: $42M A Nov 2020

Drug notes:

About:

Jobs: